放疗联合多西紫杉醇加顺铂治疗晚期非小细胞肺癌的临床研究  

Clinical Study of Docetaxel Combined with Radiotherapyin the Treatement of Advanced Non-small Cell Lung Carcinoma

作　　者：张春东[1] 丛辉[1] 赵大伟[1] 

机构地区：[1]黑龙江省医院放疗科,哈尔滨150036

出　　处：《中国肺癌杂志》2009年第6期537-538,共2页Chinese Journal of Lung Cancer

摘　　要：背景与目的探讨多西紫杉醇加顺铂联合放疗治疗晚期非小细胞肺癌的临床疗效及毒副作用。方法81例晚期非小细胞肺癌患者,随机分成两组,A组41例,应用多西紫杉醇加顺铂同步放疗组,B组40例,单纯放疗组,两组均行原发灶剂量62Gy-70Gy,区域淋巴结剂量56Gy-66Gy。结果客观近期有效率,中位生存期和1年、2年、3年生存率:放化组分别为65.8%,中位生存期14个月和63.1%、39.4%、28.9%;而单放组为44.4%,中位生存期11个月和41.6%、27.7%、11.1%,两例近期有效率有显著性差异(P<0.05)。毒副作用可耐受,无治疗相关性死亡。结论以多西紫杉醇加顺铂联合放疗治疗晚期非小细胞肺癌有效率较高,安全性较好的综合治疗方案,值得采用。Background and objective To observe the clinical effect and toxicity of multimodality therapy with a combination of radiotherapy and chemotherapy regimen ofcisplatin and docetaxel for the patients in advanced stage non-small cell lung cancer. Methods Eighty-one paients with advanced non-small cell cancer randomly assigned, 41 cases to A group treated with radiochemotherapy group, 40 to B group, receiving radiotherapy lonely. All patients received 62-70 Gy in primitive lesion and 56-66 Gy in local lymph node. Results The short-term response rate,median survival rate,1 year,2-year and 3-year survivual rate were 65.8%, 14 months, 63.1%, 39.4% and 28.9%, respectively for the radiochemotherapy group, and 44.4%, 11 months, 41.6%, 27.7% and 11.1%, respectively for the radiotherapy group. （The group comparisons were all significant at P 〈 0.05 level.） Toxicity was at an acceptable level with no treatment-related death. Conclusion 23ae multimodality therapy using radiotherapy and chemotherapy regimen of cisplatin and docetaxel was effective and safe in the treatment of advanced non-small cell lung cancer patients.

关 键 词：晚期非小细胞肺癌 化疗 放射治疗 

分 类 号：R734.2[医药卫生—肿瘤]